However, delays in the global implementation of eradication strategies, in part due to lack of political commitment, funding and competing development and health priorities meant

that the initial target for eradication by the year 2000 was missed. Nevertheless, progress continued with the certification of two more WHO Regions as polio-free: the Western Pacific Region in 2000 [14] and the European Region in 2002 [15]. In 2003, only six polio-endemic countries remained: Afghanistan, Egypt, India, Niger, Nigeria and Pakistan. Although Egypt and Niger were later declared polio-free by 2005, the remaining four countries faced various GSK1838705A concentration challenges to the eradication effort over the next 10 years. Following the elimination of type-2 wild poliovirus from human populations in 1999 when the last infection was identified in India [16], and because tOPV CCI-779 cost provides less optimum protection against poliovirus serotypes 1 and 3 in some tropical settings, the monovalent and bivalent formulations of the vaccine were introduced to more closely target and rapidly

interrupt the remaining virus types in circulation, particularly in densely populated areas of high intensity of transmission [17]. India’s greatest challenge to eradication was the sub-optimal GNS-1480 nmr effectiveness of tOPV in areas of high birth rates, poor sanitation as well as dense and migratory communities. This was particularly apparent in northern India and was only overcome by a substantial effort to push coverage rates to over 95% in particularly vulnerable populations and areas, and the careful and tactical use of mOPV and bOPV [1]. India was finally removed from the WHO list of polio-endemic countries in early 2012; an enormous achievement, considering that in 2009, India had the highest number of polio cases in the world [18]. It is expected that India will be officially certified as polio-free in 2014 [19]. The nature of poliovirus has posed its own challenge to eradication. Every child

needs to be vaccinated multiple Farnesyltransferase times to ensure full immunity, depending on the vaccine used [20]. This provides a significant logistical challenge to vaccinators, especially with migratory, displaced or hard to access populations. It can be very difficult to ascertain when and how many doses of vaccine each child has received and how many children were missed on vaccination days [1]. This can pose a high risk to immunity levels as the virus may be transmitted over large distances with little warning. Natural disasters such as floods, earthquakes, hurricanes and tsunamis can also contribute to delays in eradication efforts. These can all have a detrimental impact on communications and road and health infrastructures, in some cases making it impossible to reach people except by air. Hospitals, medical centers and cold chain storage facilities can be damaged or destroyed and local health workers displaced.